GlassScriptPhysician profile
Christopher Connor Gessel
NPI 1851732655
$28,798.25
in general payments reported to CMS, 2019-2025
38 companies · $9,486 in 2025
The $9,486 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,797 · 2022: $4,668 · 2023: $2,457 · 2024: $10K · 2025: $9,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $5,816 · Travel and Lodging: $3,740 · Education: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,343.69 |
| Consulting Fee | $5,815.50 |
| Travel and Lodging | $3,739.85 |
| Education | $433.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $4,907.10 | 2021-2025 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $4,390.94 | 2022-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $3,576.39 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $2,758.83 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,825.59 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Zoll Respicardia, INC. | $1,755.53 | 2024 | Remede System |
| Mylan Specialty L.P. | $1,349.90 | 2021-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $1,271.89 | 2021-2025 | Glassia, Aralast |
| United Therapeutics Corporation | $1,139.68 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| Genzyme Corporation | $678.62 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $650.78 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.57 | 2021-2025 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Avadel Cns Pharmaceuticals, LLC | $462.40 | 2023-2025 | Lumryz |
| Harmony Biosciences LLC | $452.60 | 2021-2025 | Wakix |
| Merck Sharp & Dohme LLC | $439.68 | 2023-2025 | Winrevair |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $405.38 | 2023-2025 | Sunosi |
| Grifols USA, LLC | $298.78 | 2022-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $248.53 | 2025 | Yupelri |
| Philips North America LLC | $243.07 | 2021-2025 | Vest Therapy Und, (Ak6) Vest Therapy, Patient Interface Software |
| Amgen INC. | $235.90 | 2021-2025 | Tezspire |
| Insmed, INC. | $228.52 | 2021-2025 | Arikayce |
| Sanofi-Aventis U.S. LLC | $199.98 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $130.07 | 2021-2023 | Airduo Digihaler |
| Verona Pharma, INC. | $123.22 | 2025 | Ohtuvayre |
| Vifor Pharma, INC. | $103.59 | 2024-2025 | Veltassa, Zemaira |
| Baxter Healthcare | $103.39 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Jazz Pharmaceuticals INC. | $95.16 | 2021-2024 | |
| Lilly USA, LLC | $42.51 | 2025 | Zepbound, Mounjaro |
| Hologic Sales and Service, LLC | $29.37 | 2024 | Myosure Tissue Removal Device |
| Electromed, INC. | $27.56 | 2023 | Smartvest |
| Ani Pharmaceuticals, INC. | $25.76 | 2022 | |
| Sandoz INC. | $25.16 | 2024 | Treprostinil |
| Janssen Pharmaceuticals, INC | $22.65 | 2022 | |
| Pulmonx Corporation | $19.30 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Inogen, INC. | $17.81 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.10 | 2022 | |
| Itamar Medical INC | $11.99 | 2023 | Watchpatone |
| Apria Healthcare LLC | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Gessel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.